

# Christian Posch

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7322354/publications.pdf>

Version: 2024-02-01

61  
papers

1,988  
citations

331642

21  
h-index

265191

42  
g-index

67  
all docs

67  
docs citations

67  
times ranked

4389  
citing authors

#	ARTICLE	IF	CITATIONS
1	Adult Onset Neurodegeneration in Nucleotide Excision Repair Disorders (<sc>NERD</sc>): Time to Move Beyond the Skin. <i>Movement Disorders</i> , 2022, 37, 1707-1718.	3.9	7
2	A female patient with a receding hairline. <i>JDDG - Journal of the German Society of Dermatology</i> , 2021, 19, 301-304.	0.8	0
3	Severe thrombocytopenia and excellent response following combined immune checkpoint inhibition for metastatic malignant melanoma. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, e89-e92.	2.4	2
4	CTLA4 promoter methylation predicts response and progression-free survival in stage IV melanoma treated with anti-CTLA-4 immunotherapy (ipilimumab). <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 1781-1788.	4.2	22
5	Patterns of care and follow-up care of patients with uveal melanoma in German-speaking countries: a multinational survey of the German Dermatologic Cooperative Oncology Group (DeCOG). <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 1763-1771.	2.5	2
6	Multiple pustular lesions in a patient with ulcerative colitis " successfully treated with TNF- $\alpha$ inhibitor. <i>JDDG - Journal of the German Society of Dermatology</i> , 2021, 19, 782-784.	0.8	0
7	Clinical impact of COVID-19 on patients with cancer treated with immune checkpoint inhibition. , 2021, 9, e001931.		46
8	Dermatomyositis requires long-term treatment with combined immunosuppressive and immunoglobulin therapy. <i>JDDG - Journal of the German Society of Dermatology</i> , 2021, 19, 456-458.	0.8	2
9	The transmembrane protein LRIG1 triggers melanocytic tumor development following chemically induced skin carcinogenesis. <i>Molecular Oncology</i> , 2021, 15, 2140-2155.	4.6	3
10	Exceptional response to anti-PD-1 treatment in a patient with metastatic cutaneous hidradenocarcinoma. <i>European Journal of Cancer</i> , 2021, 145, 143-145.	2.8	3
11	Position statement of the EADV Melanoma Task Force on recommendations for the management of cutaneous melanoma patients during COVID-19. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, e427-e428.	2.4	14
12	Outcomes after stereotactic radiosurgery of brain metastases in patients with malignant melanoma and validation of the melanoma molGPA. <i>Clinical and Translational Oncology</i> , 2021, 23, 2020-2029.	2.4	0
13	Ageing research: rethinking primary prevention of skin cancer. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 2216-2218.	2.4	6
14	Magnetic nanoparticles in theranostics of malignant melanoma. <i>EJNMMI Research</i> , 2021, 11, 127.	2.5	9
15	A fresh perspective on an established marker: S100B dynamics for early detection of melanoma recurrence. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 1386-1386.	2.4	0
16	COVID-19 in a melanoma patient under treatment with checkpoint inhibition. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, e465-e466.	2.4	10
17	Anti-BP180 autoantibody levels at diagnosis correlate with 1-year mortality rates in patients with bullous pemphigoid. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 1583-1589.	2.4	12
18	Vemurafenib-related photosensitivity. <i>JDDG - Journal of the German Society of Dermatology</i> , 2020, 18, 1079-1083.	0.8	0

#	ARTICLE	IF	CITATIONS
19	Prognostic and predictive value of PD-L2 DNA methylation and mRNA expression in melanoma. <i>Clinical Epigenetics</i> , 2020, 12, 94.	4.1	26
20	Combined immunotherapy with nivolumab and ipilimumab with and without local therapy in patients with melanoma brain metastasis: a DeCOG* study in 380 patients. , 2020, 8, e000333.		55
21	Targeting p63 Upregulation Abrogates Resistance to MAPK Inhibitors in Melanoma. <i>Cancer Research</i> , 2020, 80, 2676-2688.	0.9	14
22	Clinical characteristics and treatment outcomes of 36 pyoderma gangrenosum patients â€” a retrospective, single institution observation. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, e474-e475.	2.4	3
23	Clinical melanoma characteristics and survivalâ€”a single-center retrospective study between 2000 and 2010. <i>Wiener Medizinische Wochenschrift</i> , 2019, 169, 323-330.	1.1	2
24	Mapping phospho-catalytic dependencies of therapy-resistant tumours reveals actionable vulnerabilities. <i>Nature Cell Biology</i> , 2019, 21, 778-790.	10.3	24
25	Dermatologie â€” Die Melange des CafÃ©s. <i>JDDG - Journal of the German Society of Dermatology</i> , 2019, 17, 474-475.	0.8	1
26	A dual pathway inhibition strategy using BKM120 combined with vemurafenib is poorly tolerated in BRAF V600<sup>E/K</sup> mutant advanced melanoma. <i>Pigment Cell and Melanoma Research</i> , 2019, 32, 603-606.	3.3	18
27	Apremilast in psoriasis â€” a prospective realâ€”world study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018, 32, 254-259.	2.4	54
28	MEK/CDK4,6 co-targeting is effective in a subset of NRAS, BRAF and â€”wild typeâ€” melanomas. <i>Oncotarget</i> , 2018, 9, 34990-34995.	1.8	13
29	The lincRNA MIRAT binds to IQGAP1 and modulates the MAPK pathway in NRAS mutant melanoma. <i>Scientific Reports</i> , 2018, 8, 10902.	3.3	19
30	The role of wide local excision for the treatment of severe hidradenitis suppurativa (Hurley grade III): Retrospective analysis of 74 patients. <i>Journal of the American Academy of Dermatology</i> , 2017, 77, 123-129.e5.	1.2	52
31	Recent advances in uveal melanoma treatment. <i>Medicinal Research Reviews</i> , 2017, 37, 1350-1372.	10.5	23
32	Dr. Christian Posch â€” PreistrÃ¤ger des Ã–sterreichischen Wissenschaftspreis der Ã–GDV. <i>JDDG - Journal of the German Society of Dermatology</i> , 2017, 15, 1174-1174.	0.8	0
33	Phosphoproteomic Analyses of NRAS(G12) and NRAS(Q61) Mutant Melanocytes Reveal Increased CK2 Kinase Levels in NRAS(Q61) Mutant Cells. <i>Journal of Investigative Dermatology</i> , 2016, 136, 2041-2048.	0.7	28
34	ABCB5-Targeted Chemoresistance Reversal Inhibits Merkel Cell Carcinoma Growth. <i>Journal of Investigative Dermatology</i> , 2016, 136, 838-846.	0.7	19
35	Searching for the Chokehold of NRAS Mutant Melanoma. <i>Journal of Investigative Dermatology</i> , 2016, 136, 1330-1336.	0.7	14
36	Oncogenic KIT mutations in different exons lead to specific changes in melanocyte phospho-proteome. <i>Journal of Proteomics</i> , 2016, 144, 140-147.	2.4	7

#	ARTICLE	IF	CITATIONS
37	The burden of malignant melanoma – Lessons to be learned from Austria. <i>European Journal of Cancer</i> , 2016, 56, 45-53.	2.8	31
38	Pharmacological inhibitors of c-KIT block mutant c-KIT mediated migration of melanocytes and melanoma cells <i>in vitro</i> and <i>in vivo</i> . <i>Oncotarget</i> , 2016, 7, 45916-45925.	1.8	9
39	Acyl protein thioesterase 1 and 2 (APT-1, APT-2) inhibitors palmostatin B, ML348 and ML349 have different effects on NRAS mutant melanoma cells. <i>Oncotarget</i> , 2016, 7, 7297-7306.	1.8	29
40	<i>Mycoplasma pneumoniae</i> – associated mucositis – case report and systematic review of literature. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2015, 29, 595-598.	2.4	42
41	Combined Inhibition of MEK and Plk1 Has Synergistic Antitumor Activity in NRAS Mutant Melanoma. <i>Journal of Investigative Dermatology</i> , 2015, 135, 2475-2483.	0.7	51
42	Detection of GNAQ mutations and reduction of cell viability in uveal melanoma cells with functionalized gold nanoparticles. <i>Biomedical Microdevices</i> , 2015, 17, 15.	2.8	18
43	The Risk of Melanoma in Pilots and Cabin Crew. <i>JAMA Dermatology</i> , 2015, 151, 450.	4.1	29
44	The Risk of Melanoma in Airline Pilots and Cabin Crew. <i>JAMA Dermatology</i> , 2015, 151, 51.	4.1	83
45	Merkel cell carcinoma: mitoses, expression of Ki67 and bcl2 correlate with disease progression. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2015, 29, 542-548.	2.4	19
46	Melanoma Cell-Intrinsic PD-1 Receptor Functions Promote Tumor Growth. <i>Cell</i> , 2015, 162, 1242-1256.	28.9	507
47	Metformin and trametinib have synergistic effects on cell viability and tumor growth in NRAS mutant cancer. <i>Oncotarget</i> , 2015, 6, 969-978.	1.8	61
48	Melanoma immunotherapy. <i>Cancer Biology and Therapy</i> , 2014, 15, 665-674.	3.4	73
49	Comparative profile of cutaneous adverse events: BRAF/MEK inhibitor combination therapy versus BRAF monotherapy in melanoma. <i>Journal of the American Academy of Dermatology</i> , 2014, 71, 1102-1109.e1.	1.2	67
50	Single-point mutation detection in RNA extracts using gold nanoparticles modified with hydrophobic molecular beacon-like structures. <i>Chemical Communications</i> , 2014, 50, 3018-3020.	4.1	20
51	Efficacy of intravenous immunoglobulins in livedoid vasculopathy: Long-term follow-up of 11 patients. <i>Journal of the American Academy of Dermatology</i> , 2014, 71, 738-744.	1.2	50
52	Low-dose inhalation of interleukin-2 bio-chemotherapy for the treatment of pulmonary metastases in melanoma patients. <i>British Journal of Cancer</i> , 2014, 110, 1427-1432.	6.4	26
53	Cryopyrin-Associated Periodic Syndrome. <i>Pediatric Dermatology</i> , 2014, 31, 228-231.	0.9	10
54	DNA and aptamer stabilized gold nanoparticles for targeted delivery of anticancer therapeutics. <i>Nanoscale</i> , 2014, 6, 7436-7442.	5.6	65

#	ARTICLE	IF	CITATIONS
55	Mutant <i>NRASQ61</i> shares signaling similarities across various cancer types - potential implications for future therapies. <i>Oncotarget</i> , 2014, 5, 7936-7944.	1.8	22
56	A Prospective Study of Mobile Phones for Dermatology in a Clinical Setting. <i>Journal of Telemedicine and Telecare</i> , 2013, 19, 213-218.	2.7	35
57	Combined targeting of MEK and PI3K/mTOR effector pathways is necessary to effectively inhibit NRAS mutant melanoma in vitro and in vivo. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 4015-4020.	7.1	203
58	NRAS mutant melanoma - undrugable?. <i>Oncotarget</i> , 2013, 4, 494-495.	1.8	19
59	Animal-type melanoma tumor cell invasion of dermal lymphatics and molecular identification of lymph node metastasis. <i>JDDG - Journal of the German Society of Dermatology</i> , 2012, 10, 38-41.	0.8	1
60	Perianal ulcer amebiasis cutis. <i>JDDG - Journal of the German Society of Dermatology</i> , 2011, 9, 649-650.	0.8	2
61	Analysis of liver function in renal transplant recipients undergoing C2-monitoring for cyclosporine. <i>Transplant International</i> , 2008, 21, 223-233.	1.6	2